NWRN
vs
S
Swiss Market Index
NWRN
Over the past 12 months, NWRN has significantly outperformed Swiss Market Index, delivering a return of +117% compared to the Swiss Market Index's +14% growth.
Stocks Performance
NWRN vs Swiss Market Index
Performance Gap
NWRN vs Swiss Market Index
Performance By Year
NWRN vs Swiss Market Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Newron Pharmaceuticals SpA
Glance View
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
